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Abstract. There are vibrant developments of optical imaging systems
and contrast-enhancing methods that are geared to enhancing surgi-
cal vision and the outcome of surgical procedures. Such optical tech-
nologies designed for intraoperative use can offer high integration in
the operating room compared to conventional radiological modali-
ties adapted to intraoperative applications. Simple fluorescence epi-
illumination imaging, in particular, appears attractive but may lead to
inaccurate observations due to the complex nature of photon-tissue in-
teraction. Of importance therefore are emerging methods that account
for the background optical property variation in tissues and can offer
accurate, quantitative imaging that eliminates the appearance of false
negatives or positives. In parallel, other nonfluorescent optical imaging
methods are summarized and overall progress in surgical optical imag-
ing applications is outlined. Key future directions that have the potential
to shift the paradigm of surgical health care are also discussed. C©2010
Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3523364]
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1 Introduction
Optical imaging is the primary surgical visualization modality
by means of the surgeon’s visual perception. Similarly, optical
microscopes have been adapted to surgical systems for improv-
ing resolution. Human vision is however significantly limited to
visualizing only superficial contrast. In addition, despite its abil-
ity to efficiently recognize anatomical features, human vision
can distinguish only a relatively small number of spectral fea-
tures and virtually no molecular-based features, which results in
reduced contrast for separating cancer from surrounding tissue.
The emergence of fluorescence imaging offers a potent modality
for improving the surgical outcome, by imparting specific func-
tional and molecular contrast and by allowing penetration of
several millimeters to centimeters into tissue. In addition, elab-
orate spectral imaging or high-resolution methods have shown
potential for accurately distinguishing tissue fluorochromes and
improving the physiological information available to the sur-
geon.
Many of the original systems described for intraoperative
optical imaging operated as modifications to surgical micro-
scopes or as epi-illumination (photography/video) fluorescence
systems. In addition, the use of nonspecific dyes enhanced vi-
sualization of vasculature and abnormal vessel permeability but
failed to accurately correlate with remnant disease or locore-
gional microfoci. More recently, there is shift toward engineer-
ing novel contrast mechanisms, typically based on targeting
molecular features of cancer cells. In addition, advanced optical
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technology based on image correction for tissue attenuation vari-
ation, hyperspectral methods, optical coherence tomography, or
optoacoustics are considered for improving surgical visualiza-
tion over human vision or photography. This review illuminates
developments in intraoperative optical imaging strategies and
technical advancements. Particular weight is given to discussing
novel trends that can account for the various effects of photon-
tissue interactions and reduce the number of false positives and
false negatives that may be present in simple epi-illumination
(photographic) imaging approaches. Imaging examples and ap-
plications are summarized, and highly promising directions for
clinical propagation are outlined (see Table 1).
2 Intraoperative Imaging Using Organic
Fluorescent Dyes
Since the original use of fluorescein in the 1940s and 1950s,1, 2
several fluorochromes, including fluorescent photosensitizers,
have been investigated for their ability to enhance margin
delineation, including indocyanine green (ICG),3 fluorescein-
albumin,4 and porphyrins.5, 6 ICG and fluorescein dyes7 are
nonspecific dyes with a long history of clinical use. Both dyes
are general markers of blood pooling because they are bound to
serum proteins and outline the vascular system. As such, they
are used to outline areas of perfusion and areas of high vascular
permeability (leakage), such as in eye angiography, although
some photochemical limitations have been noted.8 Other uses
and indications have been described, spanning from microscopy
uses in cellular biology to hepatic and cardiac function studies.
ICG absorbs light with a maximum at 805 nm and exhibits
1083-3668/2010/15(6)/066024/12/$25.00 C© 2010 SPIE
Journal of Biomedical Optics November/December 2010  Vol. 15(6)066024-1
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 1/8/2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
Ntziachristos, Yoo, and van Dam: Current concepts and future perspectives on surgical optical imaging . . .
Table 1 Optical imaging systems considered for surgical imaging.
Maximum depth
Technology Resolution Quantification of operation Example Refs.
Modified microscope 5–10 μma N/A 0.1 mm 9, 19
OCT 1–10 μm N/A 1 mm 62, 65
Epi-illumination imaging/video 20μ–5 mmb No >1 cm 11, 13
Epi-illumination imaging/video with color 20μ–5 mmb No >1 cm 14, 15
SFI with correction 20μ–5 mmb Yes >1 cm 23, 24
Optoacoustic imaging 50–200μ Yes >1 cm 76, 78
aThis resolution is reported for imaging tissue in vivo using conventional microscopy. Confocal or two-photon methods can reject out-of-focus contributions and offer
diffraction-limited resolution.
bResolution in epi-illumination imaging approaches depends strongly on the depth of operation. 20μ is reported for superficial imaging in the visible, but the resolution
drops significantly when imaging signals from deeper in tissues.
maximum fluorescence emission at 835 nm, whereas fluores-
cein absorbs light with a maximum at 494 nm and fluoresces
with a maximum at 591 nm. Therefore, ICG is suited for deep-
tissue imaging, because the near-infrared wavelengths (i.e.,
650–950 nm) are attenuated significantly less than the visible
wavelengths by tissue, and penetration depths on the order of
several centimeters can be achieved. Other nonspecific dyes
have also been explored in different intraoperative applications,
as described in the following. Typically, modified microscopes
have been used for visualization as shown in Fig. 1. Modifi-
cations span from the use of appropriate light sources and fil-
ters to appropriately excite different fluorochromes of interest
to advanced spectral imaging and custom made additions that
significantly improve imaging performance as outlined in the
following.
2.1 Tumor Delineation
Intraoperative imaging studies involving ICG or fluorescein have
been performed for outlining gliomas. Kuroiwa et al.9 reported
on a fluorescence imaging system that modified a Zeiss OPMI
surgical microscope using appropriate filters for illumination
and selection of signals emitted from fluorescein, employed
for glioma surgery. Fluorescein was employed to outline ar-
eas of blood-brain barrier disruption due to invasive tumors.
Significant fluorescence enhancement was seen from tumors
compared to surrounding tissues; however, no analytical results
on remnant disease or follow-up studies were carried out in
the study. Figure 2 shows pre- and postoperative MRI images,
intraoperative anatomy and fluorescence images, and correla-
tive histology from the brain surface of human who suffered
malignant glioma resection by aid of this setup. In a similar
implementation, Haglund et al. employed ICG for determina-
tion and resection of glioma margins in rat10 and human3 brain.
The imaging system used a 100-W tungsten-halogen bulb as an
excitation light source, filtered using a long-pass interference
filter to select light of >690-nm wavelengths. Imaging was per-
formed to outline primary tumor margins and remnant disease
after tumor resection. The study observed similar contrast en-
hancement from the tumor area and different ICG-clearance ki-
netics between the malignant and nonmalignant areas. Optically
guided microscopic resection demonstrated 93% specificity and
89.5% sensitivity in tumor detection.
2.2 Organ Viability
Besides the delineation of tumor borders, ICG has been further
used in the intraoperative evaluation of organ viability. Holm
Fig. 1 Schematic representation illustrating modified epi-illumination
microscope system for intraoperative fluorescence imaging. Light from
a light source is filtered at wavelengths appropriate for excitation of
the fluorochrome of interest and directed to the specimen through
the microscope objective using a dichroic mirror. Fluorescence light
emitted from tissue is collected from the same objective, filtered by the
emission filter, and detected using a CCD camera.
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Fig. 2 Human malignant glioma surgery using fluorescein imaging: (a) Preoperative (upper) MRI image showing a large tumor enhancing in the right
frontal lobe and postoperative (lower) MRI image with no enhanced tumor; (b) intraoperative image of anatomical vision using ordinary microscope;
(c) intraoperative image of fluorescein from brain tumor using modified microscope for fluorescence imaging; (d) histological examination of
nonfluorescence area, which is found as a necrotic area; and (e) histological examination of fluorescence area, which shows a significant number
of tumor cells.
et al.11 for example, have employed ICG to determine the ef-
ficacy of skin-flap perfusion, while Kubota et al.12 assessed
the success of blood-vessel reconstruction in living-donor liver
transplantation patients. Similarly, Takahashi et al.13 employed
ICG imaging for the evaluation of graft patency of patients
during off-pump coronary artery bypass grafting. Imaging in
these applications was based on commercially available epi-
illumination near-infrared (NIR) imaging systems operating in
video mode, using appropriate excitation light for ICG and
cutoff filters for fluorescence detection.
Nakayama et al.14 have also developed a video system for
intraoperative imaging of small animals and demonstrated in-
traoperative visual assessment of cardiac muscle viability in
rats using the IRDye78-CA and the IR-786 NIR dyes. The
IRDye78-CA stays intravascular and exhibits rapid distribution
and clearance to delineate blood flow in vivo, whereas the IR-
786 was employed to assess myocardial perfusion. The system
developed combined color and NIR fluorescence views that run
in parallel to achieve real-time imaging. NIR excitation was
via a custom 771-nm, 250-mW laser diode system at a flu-
ence rate of 50 mW/cm2. White-light excitation was also em-
ployed via a 150-mW halogen lamp, depleted of wavelengths
greater than 700 nm. Data were acquired assuming sequential
injection of dyes because a single excitation wavelength was
employed. Occluded vessels and a blood defect were visible
in the NIR. Potential application of the technology was as-
sumed to be the possible guiding of revascularization or the
assessment of the biodistribution of targeted gene therapy to
specific myocardial regions. A similar system, developed by De
Grand and Frangioni15 utilized halogen sources instead of laser
diodes to generate 5 mW/cm2 NIR excitation light over a 20-
cm-diam surgical field and was similarly employed to visualize
vascular perfusion in 35-kg pigs using ICG. Figure 3 shows
the setup and an intravascular mapping image of the coronary
circulation.
2.3 Lymphatic Imaging
Lymph-node mapping has also been considered in intraopera-
tive imaging using NIR organic dyes.16–18 Parungo et al.16, 17
and Tanaka et al.18 used a system similar to the one shown in
Fig. 3(a) to image the NIR fluorophores HSA-78 and HSA800.
HSA-78 was made of human serum albumin (HSA) covalently
conjugated to the IRDye78 (LI-COR, Lincolin, NE), whereas
HSA800 was also made of HSA covalently conjugated to the
CW800 fluorochrome (LI-COR, Lincolin, NE). Both molecules
exhibited similar characteristics, with HSA800 attaining a hy-
drodynamic diameter of 7.4 nm, and 784- and 802-nm excitation
and emission wavelengths, respectively, and HSA-78 having
7 nm of hydrodynamic diameter and 778 nm, 795 nm excita-
tion and emission peak respectively. HSA-78 and HAS800 were
found in two or more draining nodes compared to larger moi-
eties, such as quantum dots, which migrated only to the first
draining lymph node. Tanaka et al.18 also considered a modified
dual-camera video system with fluence rates for NIR and white-
light imaging in the range of 0–5 and 0–1 mW/cm2, respectively.
Spatial resolution at the field of view (FoV) of 20 × 15 cm was
625 μm and, at a FoV of 4 × 3 cm, was 125 μm. Using this sys-
tem, sentinel lymph-node mapping and image-guided resection
of swine tumors were performed using injection of ICG, of the
NIR fluorophore HSA800 and of quantum dots. HSA800 was
similarly considered herein for mapping all draining nodes, com-
pared to larger-sized tracers that better outline one primary node.
Intraoperative imaging applications have thus largely demon-
strated the feasibility and flexibility of fluorescence imag-
ing use in the operating room. Conversely, nonspecific dyes,
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Fig. 3 Concurrent anatomy and NIR fluorescence imaging system for surgical guidance: (a) Architecture of imaging module. Fluorescence excitation
light is provided using two halogen sources with appropriate filtration. NIR- and IR-depleted white light is supplied by ring light connected to a
halogen source. (b) Color video image of surgeon’s view. (c) Same color image with the pseudocolored overlay of the NIR fluorescence. The image
shows intravascular mapping of the coronary circulation using ICG on a heart of a pig. The artery and vein are indicated by an arrow and arrowhead,
respectively.
combined with the qualitative nature of photographic and video
epi-illumination imaging systems have not yet allowed for high
surgical impact, because these feasibility studies did not gen-
erally generate statistically important samples demonstrating
improved surgical outcome or did not reach sufficient quantita-
tive ability or image fidelity, although they may be particularly
useful in interrogation of physiology. For this reason, a second
generation of targeted contrast and advanced imaging systems
was considered for improving the identification of disease, as
described in the next section.
3 Imaging of Induced Porphyrins
Similarly to the Kuroiwa et al. study,9 Stummer et al.19 employed
a modified surgical microscope (Zeiss OPMI CS-NC, Germany)
to operate in fluorescence mode for fluorescence-guided tumor
removal. The study imaged protoporphyrin IX (PpIX) induced
endogenously at the site of malignant gliomas by administer-
ing 5-aminolevulinic acid (ALA) at a dose of 20 mg/kg at
3 h before induction of anesthesia. PpIX has characteristic red
emission peaks at 635 and 704 nm under UV/blue-light exci-
tation. A xenon light source coupled to the microscope, which
can be switched from normal white light to violet-blue excita-
tion light (375–440 nm), was employed in the study, whereas
for optimum light delivery, a commercial liquid light guide was
used to deliver ∼ 40 mW/cm2 irradiance at a distance of 5 cm
from its tip. Transmission characteristics of excitation and flu-
orescence filters were chosen to transmit part of the remitted
excitation light. Thereby, the observer retained an impression
of tissue detail, next to tumor porphyrin fluorescence. Detection
was achieved by an integrating three-chip CCD camera opti-
mized for red-light detection. A series of studies5, 6, 19 on >100
patients observed that removing “solidly fluorescing” tissue im-
proved patient survival. It was further seen that residual tissue
exhibiting “vague fluorescence” represented infiltrating tumor
of intermediate or low cellular density. Overall, the potential
of ALA-PpIX fluorescence-guided resection was demonstrated,
but the overall impact of the methodology was limited by two
facts, i.e., that only a single ALA dose and time interval was used
and that the assessment of the tissue fluorescence was qualitative
and subjective.
To further study the potential of induced porphyrin-assisted
intraoperative imaging, Stummer et al.20 launched a multicen-
ter prospective-randomized clinical phase-III-trial in Germany,
wherein 322 patients aged 23–73 years with suspected malig-
nant glioma were randomly assigned to two groups (i.e., conven-
tional brain surgery using white light or to fluorescence-guided
surgery). The interim trial on 270 patients evaluated resections
as defined by pre- and postoperative magnetic resonance imag-
ing (MRI), and studied the impact of resection on progression-
free survival, neurological morbidity, and overall survival. The
study demonstrated almost a doubling of complete resections
of glioma tumors in fluorescence-guided surgery, leading into
longer progression-free patient survival compared to conven-
tional microsurgery under white light. More recent studies con-
firm improved surgery outcome and patient survival (16.7 versus
11.8 months, P < 0.0001).21, 22
4 Spectral Imaging
To improve on the detection accuracy of porphyrins, or other flu-
orochromes used in intraoperative application, spectral fluores-
cence imaging (SFI) was considered for glioma resection.23, 24
In this technique, imaging at five spectral bands (495, 543, 600,
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640, and 720 nm; each band of 20 nm fullwidth at half maxi-
mum) was performed, utilizing a long working distance (∼50
cm), 3-cm FoV, large depth of field (∼2 cm), and high spa-
tial resolution (∼150 μm). Illumination was provided from a
50-W mercury lamp, which is filtered for 405 ± 15 nm exci-
tation wavelength. Fluorescence signals were collected by the
same lens used for illumination and were separated with a 50:50
beamsplitter to an imaging path and a fluorescence spectroscopy
path that could obtain measurements from a point on the tissue
surface. Images were detected using a CCD camera, and spectral
separation was achieved using a filter wheel containing five dif-
ferent bandpass filters, which were rotated in front of the CCD
camera. Tissue autofluorescence at 640 ± 20 nm was calculated
by linearly interpolating the fluorescence spectra in the 600 ± 20
and 710 ± 20 nm bands and employed to improve the contrast of
red Photofrin fluorescence centered at ∼640 nm. However, the
utilization of the complete spectral features of the system in the
clinical studies, imaging patients administered with Photofrin
and undergoing photodynamic therapy, was limited by slow ac-
quisition times (tens of seconds). It was also found that blood
vessels and hyperemic regions affected the imaging accuracy,
because image artifacts were present due to variations in tis-
sue optical properties not related to malignancy. Furthermore,
the frequent switching between the SFI system and the surgical
microscope complicated operations.
In general, spectral imaging has shown advantages in sepa-
rating and better identifying target fluorochromes, and this tech-
nology has the potential to improve the performance of intra-
operative imaging.25 Recently, real-time multispectral systems
(color and other spectral bands) have been reported for three-
camera intraoperative imaging.26, 27 The system by Themelis
et al.27 attains the potential for real-time attenuation correction,
based on spectral information, as described in the following.
Therefore, besides the subtraction of autofluorescence, SFI can
be employed in ways that correct also for optical property vari-
ations and improve the imaging accuracy.
5 Imaging Using Quantum Dots
Quantum dots have also been considered for intraoperative pro-
cedures. Frangioni and colleagues have investigated the use of
quantum dots to assess lymphatic drainage from the site of the
primary tumor.17, 18, 28–30 The sentinel lymph-node concept states
that if the first lymph node to receive lymphatic drainage from
a tumor site (the sentinel node) does not contain tumor cells,
it is unlikely that the tumor has metastasized to the lymphatic
system. Several studies have indicated that, in several cancers
(for example, breast cancer or melanoma), the sentinel lymph
node accurately reflects the tumor status of regional nodes. Iden-
tification of the sentinel node is typically achieved by the use
of radioactive tracers (Technetium 99 m) using a γ camera and
the injection of a blue dye that can help in the visual identi-
fication of the node. To avoid the use of radioactivity and the
inability of blue dyes to be detected when deep in tissue, Kim
et al. demonstrated the utility of intraoperative epi-illumination
fluorescence imaging to locate sentinel lymph nodes 1 cm deep
in tissue,28 in several locations, including the pleural space,16, 29
esophagus17 or lung30 of pigs16, 17, 28, 30 and rats.16, 29 The quan-
tum dots employed for injection in these applications attained
a hydrodynamic diameter of 15–20 nm, fluorescence emission
at 840–860 nm, an aqueous quantum yield >13%, and a sta-
ble oligomeric phosphine coating for avoiding photobleaching.
These quantum dots permitted imaging of sentinel lymph-node
drainage in real time using excitation fluence rates of 5 mW/cm2
and concentrations in the subnanomole range. Quantum dots re-
mained localized to the subcapsular and intermediate sinuses
of the sentinel lymph nodes. The particle size of the tracer used
eventually determines the migration time in sentinel lymph-node
mapping. Particles of <5 nm partition into blood, and those be-
tween 5 and 10 nm can migrate through nodal tissue often,
resulting in false positives, whereas those >1000 nm largely
remain at the injection site. The major limitation of the use
of quantum dots concerns their potential toxicity because they
contain heavy metals at their cores. The authors of these studies
observed no evidence of acute toxicity.17, 18, 28–30 Although most
of the injected dose is removed by resecting nodal tissue, so
toxicity may in fact be negligible, their use in humans may be
problematic.
6 Imaging Viral Replication
An alternative to imaging extrinsically administered dyes and
nanoparticles or induced fluorescence has recently emerged via
the use of virally induced contrast. In particular, the use of
a genetically modified oncolytic HSV (NV1066) carrying the
transgene encoding for enhanced GFP was considered for accu-
rate delineation of primary or metastatic cancer cells because the
virus has shown selective infection of and replication in cancer
cells. This approach results in highly cancer-specific expression
of GFP that can identify even small foci of malignant tissue;
however, clinical propagation requires careful consideration of
biosafety issues.
Using a fluorescence laparoscopic and endoscopic system,
Adusumilli et al. demonstrated that a single dose of NV1066,
administered either locally (intratumoral or intracavity) or sys-
temically, detected locoregional and distant disease throughout
the body.31 The imaging apparatus, co-developed with Olympus
America, Inc. (Olympus America, Scientific Equipment Divi-
sion, Melville, New York) imaged in both bright-field and fluo-
rescent modes permitting the detection of GFP. Using this sys-
tem, minimal residual disease following cytoreductive surgery
and improvement of the completeness of cure-intended resection
in mice was showcased.31 Detection of breast cancer lymph-
node metastases in mice32, 33 and detection of many kinds of
tumors and metastases, such as peritoneal carcinomatosis, pan-
creatic cancer, colorectal cancer, gastric cancer, lung cancer,
pleural disease, etc., in mice and hamsters, was also shown.34
Figure 4 shows an example of expressed green fluorescence in
lymphatic metastases by NV1066 injection. Possible contami-
nation of GFP signals by tissue autofluorescence was avoided by
appropriate filtering around the maximum of the GFP emission
wavelengths.
7 Magneto-Fluorescent Nanoparticles
Multimodal nanoparticles or other dual-labeled contrast agents
that attain contrast for both MRI and optical methods have been
used to permit preoperative MR visualization and intraoper-
ative fluorescence imaging. This strategy combines the supe-
rior whole-body imaging ability using MR with high-resolution
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Fig. 4 Intraoperative imaging of enhanced GFP from lymphatic metastases of a mouse by infection with NV1066, an oncolytic herpes vector.
Metastases in the paraaortic lymph nodes as well as adrenal metastases were revealed (a). Fluorescent endoscopic examination also revealed the
location of metastases in (b) cervical, (c) axillary, (d) mediastinal, and (e) celiac lymph nodes from lung, breast, and gastric cancers, respectively.
fluorescence imaging in intraoperative environments. Magnetic
nanoparticles (10–100 nm) have long blood half-lives because
they are too large to undergo renal elimination and too small to be
easily recognized by phagocytes. They are eventually internal-
ized, predominantly by cells of the reticuloendothelial system,
and their superparamagnetic iron is dissolved and joins normal
iron pools. In response to these issues, long-circulating magnetic
nanoparticles have been investigated as magnetic resonance con-
trast agents, with the hope of proving better delineation of brain
tumors. It is also possible to conjugate the nanoparticles with
other molecules to manufacture “targeted probes” (i.e., particles
with specificity to specific cellular components) or for colabel-
ing them to create dual-label contrast agents and probes, for
example, using fluorescence labels matched to desired surgical
applications.
Kircher et al.35 explored a multimodal (NIR fluorescent
and magnetic) nanoparticle based on a cross-linked iron oxide
(CLIO) as a preoperative MRI contrast agent and intraopera-
tive optical probe using a model of rat gliosarcoma with stably
GFP-expressing 9L glioma cells. Noninvasive optical imaging
was performed on rats implanted with 5 μL of the 9L-GFP-
gliosarcoma cell suspension (106 cells in Hank’s Buffered Salt
Solution) in the striatum at a depth of 3 mm from the dural
surface using a custom-built multispectral photographic imag-
ing system (Siemens Medical Systems, Germany). They ob-
tained images of a rat after craniotomy and exposition of the
tumor, 24 h after i.v. injection of CLIO nanoparticles conjugated
with the Cy5.5 fluorescent dye (GE Healthcare Life Sciences;
former Amersham BioSciences). In addition to Cy5.5 images,
white-light images were obtained for spatial colocalization of
fluorescence images with anatomical features, whereas images
acquired in the GFP channel served as the gold standard for
delineation of true tumor extent. Figure 5 shows brain tumor
margin delineation by Cy5.5-CLIO and congruent GFP sig-
nals. Using microscopy, they also found that Cy5.5-CLIO was
strongly associated with CD11b-positive cells (microglia and
macrophages) and less with GFP-positive cells (tumor cells).
The approach further demonstrated the potential of linking pre-
operative MR findings with intraoperative procedures using the
same contrast method.
Recently, Koyama et al.36 synthesized and tested a single-
polyamidoamine dendrimer-based hybrid probe, using gadolin-
ium and the Cy5.5 fluorochrome for dual MR and nearinfrared
imaging, respectively, also allowing pre- and intraoperative lo-
calization of the sentinel lymph node. They injected the agent
into mammary glands of 10 normal mice to examine the lym-
phatic drainage from the breast. Immediately after the MRI scan,
they performed an NIR optical imaging study with the commer-
cial Maestro spectroscopic imaging unit (CRI, Waltham, Mas-
sachusetts) using an excitation 615–665 bandpass filter and an
emission 700-nm long-pass filter. Because of interfering fluo-
rescence from the injection site, the supraclavicular or lateral
thoracic nodes close to the injection site could not be readily
detected even though they were readily identified on the MRI.
However, once the skin was removed, all sentinel lymph node
were easily identified and resected under NIR image-guided
surgery.
8 Fluorescence Imaging with Labeled Cells
Other targeted approaches with fluorescence-labeled carriers
have also been considered for surgical applications. Flaumenhaft
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Fig. 5 Intraoperative brain tumor delineation with multimodal nanoparticle. After intravenous injection of Cy5.5-CLIO, i.e., fluorescent nanoparticle,
a rat bearing GFP expressing 9L glioma tumor was imaged with (a) white light, (b) GFP channel, and (c) Cy5.5 channel, intraoperatively. After tumor
resection, histological finding (D) and fluorescence microscopy at GFP (e) and Cy5.5 (f) channel on tumor tissue were performed. Cy5.5 fluorescence
from nanoparticle clearly visualizes the tumor, as indicated by the correlation with the tumor extent as determined by GFP fluorescence.
et al.37 imaged thrombus formation in the coronary, carotid,
and femoral vessels of pigs in real time using IR-786-labeled
platelets that fluoresced at 800 nm. The observations attained
a signal-to-background ratio ≥2 maintained for at least 2 h.
The imaging system utilized three CCD cameras and separated
three spectral bands, using two dichroic mirrors, allowing
color imaging (400–680 nm) and imaging of two distinct
fluorochromes at 700–725 and >795-nm spectral bands.37 The
ability to image at two common spectral bands allows the use
of popular fluorescent labels without the need to switch filters
as would be the case if a single camera was utilized for fluo-
rescence imaging. It was also possible therefore to assess blood
flow by imaging methylene blue that fluoresced at 700 nm. The
light source in this case consisted of 800 light-emitting diodes
(LEDs) in a low-profile unit comprised of square modules. Each
module was roughly 25 × 25 mm and housed 20 LEDs, driven
by custom-designed, scalable electronics and utilizing a cooling
system to dissipate heat generated by the LEDs. The source
was contained in a sterile drape and generated fluence rates of
12.5–25 mW/cm2 to excite the two fluorochromes and supply
white-light illumination. With this approach, platelet-rich,
actively growing clots were monitored and quantified with
respect to size and kinetics after injury to vessels, cutaneous in-
cisions, intravascular stent insertion, or introduction of embolic
coils.
9 Fluorescence Imaging with Labeled Probes
Although significant volume of work has been performed with
the use of intrinsic tissue contrast or with nonspecific fluores-
cent dyes or nanoparticles, there is high potential to employ
new classes of dyes developed for targeted tumor imaging in
order to improve intraoperative imaging. Antibody, antibody
fragment, peptide, and minibody-based fluorescent probes can,
for example, improve the detection ability of tumor borders
(margins) or metastatic microfoci by attaching to upregulated
cancer receptors38–40 although such agents have not been
explicitly considered only for surgical imaging applications,
they can truly revolutionize the intraoperative and endoscopic
imaging capacity by dramatically increasing the sensitivity
and specificity of detection over human vision. Similarly, engi-
neered probes can capitalize on tumor-specific physiological or
molecular parameters, such as an active intracellular transport
or enzymatic upregulation.39–43 For example, activatable probes
with sensitivity to tumoral proteases have been shown to accu-
mulate at tumor margins where local inflammatory responses
degrade the quenched dyes and activate fluorescence.44
The use of labeled molecules with tissue specificity is ex-
pected to become a crucial platform in the propagation of fluo-
rescence surgical imaging into the clinic. Yet, regulatory proce-
dures need to be followed before the clinical administration of
these agents, which makes this process slow or even occasion-
ally forbidding due to the associated cost and risk. However,
there is potential to work closely with the administrative agen-
cies and with labeled agents of known safe toxicity profiles to
enable what could become a shift in the surgical paradigm.
10 Toward Accurate Fluorescence Imaging
Although photographic and video-imaging methods as de-
scribed in the above appear attractive for surgical imaging
the fluorescence imaging performance can be compromised
by three major parameters, i.e., the depth of the fluorescence
activity, the variation in tissue optical properties, and tissue
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auto fluorescence. In the near-infrared, photon diffusion and
fluorochrome depth complicate the imaging outcome by atten-
uating the fluorescence signal and by reducing the resolution.
Tissue autofluorescence (i.e., fluorescence emerging from native
tissue fluorochromes, such as collagen or NADH) may reduce
the contrast available from a targeted fluorochrome. Systems
that utilize imaging at multiple wavelengths have the potential
to differentiate autofluorescence from a fluorochrome of interest,
although the spectral response of a fluorochrome may be affected
by depth, which can complicate the spectral unmixing process.
In principle, dyes with different lifetime than that of tissue could
be used for improving detection. However, this approach re-
quires significantly more complex and expensive instrumenta-
tion. In addition, lifetime measurements, although insensitive to
the optical attenuation they depend on the depth of the dye and
its biochemical environment. Therefore, surgical imaging based
on lifetime measurements may be practically challenging.
The spatial variation of tissue optical properties can also com-
promise the performance of photographic fluorescence imaging.
For example, fluorescence activity in or under absorbing areas,
such as a highly vascular tumor, is nonlinearly attenuated as a
function of blood concentration and may show darker than in
surrounding normal tissue, which may contain less fluorochrome
but emit more light due to having overall less optical attenuation
compared to the vascular tumor. Similarly, small fluorochrome
amounts in a semitransparent or nonabsorbing lesion, for ex-
ample, a cyst or a lymph node, may appear brighter on images
compared to surrounding muscle containing similar amounts
of fluorochrome. These effects are typically corrected in tomo-
graphic systems45 but have not been thoroughly addressed in
systems developed for surgical imaging applications.
These limitations of photographic imaging have been
noted27, 46, 47 and are exemplified in Fig. 6. An approach to im-
prove on imaging performance in this case is the utilization
of measurements at multiple wavelengths. It has, for example,
been shown possible to collect data at three channels27 [Fig.
6(a)], i.e., a fluorescence channel, a light absorption channel,
and a color channel, and to implement image-correction algo-
rithms for the variation of optical absorption by tissue in real
time, yielding more accurate images of a surgical field in the
presence of hypo-/hyperemic or hypoxic areas as appropriate
for intraoperative surgical imaging. The principle of operation
is based on independently measuring background attenuation
images/video that can normalize the fluorescence images/video
captured in a separate channel. Bogaards et al.47 have also pro-
posed different ratio implementations for intraoperative fluo-
rescence imaging that offer a combination of fluorescence mea-
surements, or fluorescence and intrinsic measurements, and have
demonstrated improvements over conventional epi-illumination
imaging. Overall, methods that improve on the limitations of
conventional photographic fluorescence imaging or video will
become important as the clinical translation of such approaches
is considered.
11 Imaging of Intrinsic Signals
In addition to imaging-induced or extrinsically administered
agents, intrinsic tissue contrast (i.e., native light-tissue inter-
actions) is also considered for intraoperative procedures. For
example, optical imaging of neuronal activity has been consid-
ered for evaluating damage during neurosurgical resection, as
an alternative or surrogate method to functional MRI and elec-
trocortical stimulation mapping.48 Changes of neuronal activity
can be detected as absorption changes due to corresponding
variation in blood volume and oxygenation during functional
activity, as well as scattering changes due to ion fluxes between
neurons and glia, resulting in cell volume changes. This contrast
has been used for studying functional organization in the cat or
monkey visual cortex,49 the rodent somatosensory cortex,50 or
the human cortex in cognitively evoked functional activity51 and
functional brain mapping studies in humans.52–54
Another approach utilizes optical coherence tomography
(OCT), a technique that can offer high resolution images (1–
10 μ) of tissue structure at depths up to 1–2 mm. The primary
OCT contrast generation mechanism is backscattered light from
tissue structures, attributed to tissue scattering. Concurrent im-
provement of laser sources, beam-delivery instruments, detec-
tion schemes, and research techniques has brought significant
technological advance of OCT. As a result, OCT has been clini-
cally demonstrated in a diverse set of medical specialties, includ-
ing ophthalmology, oncology, or cardiology55 and its application
for intraoperative imaging has also been gaining attention.56–59
In ophthalmology, OCT was initially demonstrated for cross-
sectional retinal imaging in 1991.60 Since then, it has become
a key diagnostic tool in the ophthalmology community. Sev-
eral trials for surgical guide and intraoperative management
with OCT have been also evaluated. Azzolini et al. showed
the usefulness of OCT to identify macular membrane in id-
iopathic epiretinal macular membrane surgery.61 To improve
the precision of refractive surgery, Bagayev et al. showed that
the use of OCT with a specially developed algorithm of sig-
nal processing for determination of the removed corneal thick-
ness profile in situ with laser ablation is more promising com-
pared to the use of the reflected component.58 Intraoperative
OCT may also allow the identification of tissue borders and
the identification of submucosal tumor growth. OCT may be
especially effective in detecting human breast lesions due to
significant structural differences between the fibro-fatty tissue
comprising most of the breast and the densely scattering tumor
tissue that comes of from the functional epithelial network of
ducts and lobules. Boppart et al. demonstrated this potential
in rat mammary tumor models62 and also studied the detec-
tion of human breast cancer ex vivo with portable real-time
OCT.63
Brown et al. imaged the radial arteries and saphenous veins
of 35 patients scheduled for coronary artery bypass grafting us-
ing catheter-based OCT in situ prior to harvesting vessels and ex
vivo after vessel excision.64 OCT reliably demonstrated luminal
abnormalities within bypass conduits resulted from atheroscle-
rosis, trauma, or retention of thrombi. They showed the feasi-
bility of OCT in cardiac surgery as a selection tool of conduit
vessels in spite of limited tissue penetration depth and blood-
induced signal attenuation. Li et al. also demonstrated OCT of
normal and osteoarthritic cartilage during open knee surgery,65
in real time, achieving 11-μm resolution at 4 fps. The study was
performed on six patients and showed detection of structural
changes including cartilage thinning and fibrillations.
Other optical sensing approaches included spectroscopic
identification of cancerous signatures with point-to-point single-
fiber detection; however, this technique has not yet been shown
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Fig. 6 (a) Schematic of the imaging system developed to operate in real-time (video) mode and implementing concurrent fluorescence, attenuation
(intrinsic), and color measurements. All optical path lengths from the lens to the cameras are equal (not plotted in scale on the drawing). A
transillumination branch is also implemented in the system for volumetric imaging. (b) Postmortem color image of a surgically exposed mouse
abdominal area in epi-illumination mode. The two white arrows show the lumbar lymph nodes injected with a mixture of Cy5.5 fluorescence dye
and India Ink, around the inferior vena cava (double-line arrow). The orange arrow indicates an area of adipose tissue. (c) Raw fluorescence image
showing low signal intensity from the lymph nodes compared to bright background signals due to internal light attenuation due to the India ink
but increased fluorescence intensity from the adipose tissue, due to scattering of fluorescent light escaping laterally from the nodes. (d) Normalized
image showing markedly improved fluorescence quantification, correctly resolving the underlying fluorescence activity in the nodes. Reproduced
from Ref. 27.
to be practical for high-throughput intraoperative application, al-
though it demonstrates the possibility of translation from probe-
based spectroscopy to macroscopic spectral imaging.66–69
Finally, a surgical approach that has benefited from conven-
tional optical imaging and has been met with strong interest
is the use of optically guided robotic-assisted surgery,70 the
most popular technology being the Da Vinci system (Intu-
itive Surgical Inc., Sunnyvale, California).71–73 The Da Vinci
system combines a stereo endoscope with highly articulated
robotic arms that can translate surgical procedures into mini-
mally invasive environments. In this case, the surgeon operates
the robotic arms on a console, while viewing high-resolution
images of the surgical site on a monitor. In this manner, the Da
Vinci system can offer improved laparoscopy procedures and
has found use in pelvic surgery, including prostate, rectal, uter-
ine, and cervix operations71 or cardiac and gynecologic surgical
procedures.72, 73
12 Optoacoustic Imaging and Surgery
The recent emergence of various optoacoustic imaging ap-
proaches open further possibilities in photonic imaging,
including surgical optical imaging. Visualization of blood ves-
sels has been demonstrated74 and can be of importance in
vascular surgery and in identifying vital functional structures
during tumor removal. Multispectral optoacoustic tomography
(MSOT), a method developed to spectrally identify photoab-
sorbing agents, such as fluorochromes or nanoparticles75, 76 is
another optoacoustic method that can bring benefits to surgical
imaging. The ability to detect molecular probes based on their
spectral signature is of particular importance when using tar-
geted or activatable probes because typically, such agents need
to be allowed to distribute for several minutes to hours in or-
der to preferentially target cancer and activate or clear from the
circulation. Therefore, it would be impractical to monitor such
agents as absorption changes; instead, real-time MSOT would
be required for practical detection.77 Optoacoustic imaging has
also been considered in detecting lymph nodes78, 79 in small an-
imals, and depending on the light penetration conditions, such
application could also find clinical applications for superficial
nodes.
From a practical standpoint, the application of optoacoustics
to cancer delineation may require contact with tissue, which
could limit the application and FoV that can be surveyed. Con-
versely, optoacoustics can yield high-resolution imaging within
several millimeters to centimeters of depths in tissues and can
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become a very useful add-on to survey capable systems, such as
epi-illumination fluorescence imaging.
13 Summary and Outlook
Despite the highly invasive nature of many tumors, surgery re-
mains a common therapeutic approach in oncology. Mount-
ing literature reports however confirm the inaccuracy of
oncological surgery procedures.80–82 Improvements in the re-
section technique are therefore highly sought to improve sur-
vival, decrease functional loss, and increase the quality of life of
the cancer patient.83 Over the years, a variety of dyes and sys-
tems have been employed to improve margin resection. Since
the original use of fluorescein in the 1940s and 1950s1, 2 several
fluorochromes or fluorescent photosensitizers have been inves-
tigated for their ability to enhance margin delineation, including
porphyrins,5, 6 ICG,3 and fluorescein-albumin.4 Investigations
using fluorescein also continued.7 Importantly, tumor-targeting
approaches39–41 can significantly enhance the specificity of de-
tection and improve the surgical outcome. Yet, new probes with
the potential to improve cancer imaging need to be evaluated as
to their toxicity and biodistribution, which presents a significant
challenge as to their clinical translation.
Despite promising results, it has been noted that conventional
fluorescence detection based on photographic imaging lacks the
ability to accurately characterize fluorescence in tissues as it
offers crude observations6, 24 because it does not account for
variations in the detected fluorescence intensity as a function
of tissue optical property variations or the fluorochrome depth.
Therefore, the ability to offer accurate, artifact-free imaging, in
real-time mode, has been identified as an important improve-
ment for fluorescence-guided tumor surgery and accurate mar-
gin identification.24, 27, 46, 47 In response, different approaches are
emerging for improving imaging performance in fluorescence
surgical imaging. Focus is given to imaging in the NIR to avoid
interference with standard color imaging, reduce tissue autoflu-
orescence, and enable sensitivity at greater depths. In addition,
quantification is improved by using spectral schemes that can
decompose true fluorescence signals from other tissue contri-
butions. Small FoV, high-resolution approaches, such as OCT
or confocal and two-photon microscopy can also bring benefits
to surgical imaging; however, large FoV methods, such fluores-
cence imaging, may be, regardless, required to guide higher-
resolution methods. Point-detection spectroscopic approaches
have also been considered for surgical cancer identification66–68
but they cannot assess the extent of tumor infiltration; in this
case, hyperspectral imaging approaches appear more appropri-
ate for accurate tumor margin resection and overall intraopera-
tive operation.
Surgical optical imaging ties well with the surgeon’s percep-
tion of the disease and attains several attractive features, includ-
ing a practical integration in the operating room due to the small
form factor, low cost, and high-detection sensitivity and resolu-
tion for surface and subsurface detection. Compared therefore to
other imaging modalities, it attains high dissemination potential
and can find widespread clinical propagation in many surgical
oncology fields and beyond, including head and neck cancer,
otolaryngology, neurooncology, gynaecologic oncology, urol-
ogy, and thoracic surgery. It is also possible to combine optical
imaging approaches and other imaging methods, in multimodal
approaches, for example, using nuclear medicine methods, ul-
trasound imaging, or navigation methods based on whole-body
radiological images, to overall improve the procedures and surgi-
cal ability. Furthermore, optical imaging techniques are expected
to be useful not only for real-time intraoperative procedures but
also for postoperative inspection of excised tissues, resulting in
more efficient and less time-consuming examinations compared
to histopathological analyses.
Evolving fluorescence enhanced surgical vision has the po-
tential to shape the future of surgical procedures by improving
the sensitivity and accuracy of tumor delineation (circumfer-
ential resection margin), locoregional involvement, and lymph-
node interrogation. It is therefore anticipated that the technology
of dedicated intraoperative optical instrumentation and the em-
ployment of targeted agents will significantly grow in the future
to allow for improved surgical outcome using optical imag-
ing, i.e., a method with highly attractive characteristics to allow
for high dissemination and wide acceptance into the operating
room.
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